Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. The company also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Follow-Up Questions
Who is the CEO of Roivant Sciences Ltd?
Mr. Matthew Gline is the Chief Executive Officer of Roivant Sciences Ltd, joining the firm since 2017.
What is the price performance of ROIV stock?
The current price of ROIV is $19.42, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Roivant Sciences Ltd?
Roivant Sciences Ltd belongs to Biotechnology industry and the sector is Health Care
What is Roivant Sciences Ltd market cap?
Roivant Sciences Ltd's current market cap is $13.2B
Is Roivant Sciences Ltd a buy, sell, or hold?
According to wall street analysts, 13 analysts have made analyst ratings for Roivant Sciences Ltd, including 6 strong buy, 9 buy, 2 hold, 0 sell, and 6 strong sell
